News

Novo Nordisk supports new diabetes education programs in Minneapolis

BY Allison Cerra

MINNEAPOLIS — Novo Nordisk has expressed its support of new diabetes education programs created by four Minneapolis-based community organizations.

The drug maker awarded sponsorships, totaling $100,000, to the Minneapolis-St. Paul regional chapter of the American Diabetes Association, A Partnership of Diabetics, HealthEast Foundation and the Open Cities Health Center. Each of the organizations educate people living with Type 2 diabetes on how to better manage their diabetes and reduce the risk of long-term diabetes-related complications, Novo Nordisk said. The sponsorships are part of the Novo Nordisk Community Care program, which aims to promote enduring, sustainable change for people living with diabetes.

"Novo Nordisk is proud to support these community programs because they have the potential to help stem the tide of diabetes in Minneapolis," Novo Nordisk executive director of communications and public affairs Lori Moore said. "Novo Nordisk brings innovative treatments and devices to the diabetes community, but as an industry leader, we also have the opportunity and responsibility to provide resources to local organizations whose deep understanding of their constituency’s needs can make a significant impact on the way patients manage their disease. We very much look forward to seeing the programs roll out and make a difference in the communities they serve."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Omnitrope approved for Turner syndrome

BY Alaric DeArment

PRINCETON, N.J. — The Food and Drug Administration has approved a new use for a follow-on biologic made by Sandoz.

Sandoz, the generic drugs arm of Swiss drug maker Novartis, announced the approval of Omnitrope (somatropin [rDNA origin]) for children with growth failure due to Turner syndrome. Sandoz said Omnitrope was now approved for all the same indications as the reference product, Pfizer’s Genotropin.

"Sandoz is pleased to continue to expand patient access to this high-quality biopharmaceutical product, having received approvals for four new indications over the past two years," Sandoz president Don DeGolyer said. "The approval of Omnitrope for Turner syndrome will further allow us to meet the diverse needs of patients with growth-related conditions."

Omnitrope originally received approval from the FDA for pediatric growth-related disorders in 2006 under a new drug application, or NDA. Though Omnitrope is technically a follow-on biologic, no abbreviated approval pathway for follow-on biologics existed at the time, thus requiring its approval under the same pathway as the one used for branded pharmaceutical drugs.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Sears, Kmart help support Irene recovery efforts

BY Antoinette Alexander

NEW YORK — Sears and Kmart stores announced that they are supporting emergency relief efforts in a dozen states to help residents recover from Hurricane Irene’s damaging winds and floodwaters.

Sears and Kmart stores will offer discounts on recovery items in stores throughout Connecticut, Delaware, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, North Carolina, Pennsylvania, Rhode Island and Vermont.

Key discounts include:

Kmart:

  • 20% off apparel and soft home from Aug. 31 to Sept. 30, 2011

  • 10% off hardlines from Sept. 7 to Sept. 30, 2011

  • Offers exclude event and clearance sales

Sears:

  • 20% off softlines from Aug. 31 to Sept. 30, 2011

  • 10% off hardlines from Sept. 7 to Sept. 30, 2011

In addition, Sears and Kmart will work with Rebuilding Together, a nonprofit working to preserve affordable homeownership, in the coming months to provide assistance to communities in their rebuilding efforts.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?